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A B S T R A C T
Background
Erythema nodosum leprosum (ENL) is a serious immunological complication of leprosy, causing inflammation of skin, nerves, other
organs, and general malaise. Many different therapies exist for ENL, but it is unclear if they work or which therapy is optimal.
Objectives
To assess the effects of interventions for erythema nodosum leprosum.
Search methods
We searched the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The
Cochrane Library (Issue 1, 2009), MEDLINE (from 2003), EMBASE (from 2005), LILACS and AMED (from inception), CINAHL
(from 1981), and databases of ongoing trials, all in March 2009. We checked reference lists of articles and contacted the American
Leprosy Missions in Brazil to locate studies.
Selection criteria
Randomised controlled trials (RCTs) of interventions for ENL in people with leprosy.
Data collection and analysis
Two authors performed study selection, assessed trial quality, and extracted data.
Main results
We included 13 studies with a total of 445 participants. The quality of the trials was generally poor and no results could be pooled
due to the treatments being so heterogeneous. Treatment with thalidomide showed a significant remission of skin lesions compared
to acetylsalicylic acid (aspirin) (RR 2.43; 95% CI 1.28 to 4.59) (1 trial, 92 participants). Clofazimine treatment was superior to
prednisolone (more treatment successes; RR 3.67; 95% CI 1.36 to 9.91) (1 trial, 24 participants), and thalidomide (fewer recurrences;
RR0.08; 95%CI 0.01 to 0.56) (1 trial, 72 participants).We did not find any significant benefit for intravenous betamethasone compared
to dextrose (1 trial, 10 participants), pentoxifylline compared to thalidomide (1 trial, 44 participants), indomethacin compared to
prednisolone, aspirin or chloroquine treatments (2 trials, 80 participants), or levamisole compared to placebo (1 trial, 12 participants).
Mild to moderate adverse events were significantly lower in participants taking 100 mg thalidomide compared to 300 mg thalidomide
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daily (RR 0.46; 95% CI 0.23 to 0.93). Significantly more minor adverse events were reported in participants taking clofazimine
compared with prednisolone (RR 1.92; 95% CI 1.10 to 3.35). None of the studies assessed quality of life or economic outcomes.
Authors’ conclusions
There is some evidence of benefit for thalidomide and clofazimine, but generallywe didnot find clear evidence of benefit for interventions
in the management of ENL. However, this does not mean they do not work, because the studies were small and poorly reported. Larger
studies using clearly defined participants, outcome measures, and internationally recognised scales are urgently required.
P L A I N L A N G U A G E S U M M A R Y
Interventions to treat erythema nodosum leprosum, a complication of leprosy
Leprosy remains a public health issue in poorer parts of the world. In 2007 there were approximately 255,000 new cases reported
worldwide. Leprosy (or Hansen’s disease) is a chronic infectious disease. The skin and peripheral nerves of people with leprosy contain
leprosy bacteria. Leprosy can be cured with a combination of antibiotics. The immune system plays an important role in leprosy and
determines if and how the disease will develop. The response of the immune system to the antigens of the leprosy bacteria may cause
periods of inflammation in the skin and nerves, called reactions. Reactions are the main cause of acute nerve damage and disability in
leprosy and occur in about one third of people with leprosy. One type of reaction is erythema nodosum leprosum (ENL), a serious and
often chronic complication of leprosy caused by the immune system. People with ENL have red, painful swellings in the skin and often
feel ill due to fever and general malaise. There are several treatments for ENL, including the oral drugs prednisolone, thalidomide, and
clofazimine. We undertook a systematic review on this topic as it was not clear which treatments were most beneficial.
Our review included 13 randomised controlled trials involving 445 participants. These trials assessed: betamethasone (1 trial), thalido-
mide (5 trials), pentoxifylline (1 trial), clofazimine (3 trials), indomethacin (2 trials), and levamisole (1 trial). Generally, the quality of
the studies was poor and many were too small to identify important clinical differences even if they existed. Three small trials showed
benefit for thalidomide and clofazimine treatment in terms of fewer further reactions, more treatment successes, and less relapses of
ENL.
Adverse events were reported in most of the trials, but it was often not possible to compare the occurrence of any adverse events between
the experimental group and control group. Most adverse events reported were not too serious, and only a few participants could not
complete treatment due to serious adverse events or for other reasons.
Whether the interventions improved the quality of life of participants, was not evaluated in any of the trials.
Although we did not find clear benefits in these series of small, poorly-performed studies, this does not mean that these drugs do
not work in the treatment of ENL, only that scientific evidence is insufficient. Future studies should be better designed and use clear
definitions and outcomes, including long-term outcomes and quality of life measures.
B A C K G R O U N D
Description of the condition
Leprosy is a chronic infectious disease caused by the bacterium
Mycobacterium (M.) leprae. Leprosy bacteria are spread as droplets
from the nose of infected and untreated individuals (Barton 1974;
Pedley 1976; Job 2008), but the importance of other routes of
transmission is unclear. When the immune system fails to respond
effectively, the disease will develop. Often, the first sign of leprosy
is a patch on the skin, but damage to peripheral nerves may occur
as well (ILEP 2001). Leprosy develops in various clinical forms,
dependent upon the response of the immune system. The inter-
nationally accepted Ridley-Jopling classification for leprosy recog-
nises five different groups across a spectrum: tuberculoid (TT),
borderline tuberculoid (BT), borderline (BB), borderline lepro-
matous (BL), and lepromatous (LL) (Ridley 1966). Across this
spectrum, people with tuberculoid leprosy have a strong immune
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response, only a few skin patches, and a low bacterial load, while
people with lepromatous leprosy have no or very weak cell-me-
diated immunity for M. leprae, have many skin patches, and a
high bacterial load. Most people have one of the borderline forms
of leprosy: borderline tuberculoid (BT), mid-borderline (BB), or
borderline lepromatous (BL). These forms are less easy to distin-
guish and less stable, meaning that one can shift from one form to
another (Hastings 1988). An additional classification has been de-
veloped by the World Health Organization (WHO) and is based
on the number of skin lesions only. People with five or less skin
lesions are classified as having paucibacillary (PB) leprosy, while
people with six or more skin lesions are classified as having multi-
bacillary (MB) leprosy. This classification is often used in practice
to decide what type of multiple-drug therapy (MDT) should be
given to a person with leprosy (WHO 2000; Lockwood 2007).
Leprosy infection can be treated effectively with a combination
of antibiotics. Multiple-drug therapy (MDT) with the antibiotics
rifampicin, dapsone, and clofazimine was introduced in the 1980s
and is provided free by the World Health Organization (ILEP
2001; WHO 2006). Those with PB leprosy receive treatment
(dapsone and rifampicin) for six months and those with MB lep-
rosy are treated with dapsone, rifampicin, and clofazimine for 12
months (WHO 2003). Since the introduction of MDT, the num-
ber of people affected by leprosy has decreased substantially. At
the beginning of 2008 the prevalence was about 213,000 world-
wide. This is the registered number of people onMDT treatment.
The number of people newly reported in 2007 was approximately
255,000 (WHO 2008).
The body’s immune response to the leprosy bacillus may also cause
so-called ’reactions’. There are two types of potentially nerve dam-
aging reactions: type 1 reaction or reversal reaction, and type 2
reaction or erythema nodosum leprosum (ENL). Type 1, or re-
versal reaction, presents as acute inflammation in skin lesions and
nerves. Erythema nodosum leprosum presents as new, red, painful
and tender swellings in the skin, usually on the legs and arms,
and sometimes on the trunk; it varies in severity. When the reac-
tion is mild, only the skin is affected and there may be low-grade
fever. When the reaction is severe, the swellings are multiple and
may ulcerate, there may be high fever and other organs may be
inflamed, such as the nerves, eyes, joints, testes, and lymph nodes.
If neuritis is present, it is often less severe than neuritis resulting
from type 1 reaction (ILEP 2002; Kahawita 2008). Most people
with ENL have acute multiple episodes of ENL or chronic ENL
over several years. Few people experience a single acute episode of
ENL (Nery 1998; Saunderson 2000; Pocaterra 2006). Single acute
ENL reaction can be defined as one ENL episode with no recur-
rence of ENLwhilst receiving prednisolone, no increase in severity
requiring an increased steroid dose, and no recurrence after the
prednisolone has stopped. Acute multiple ENL reaction is defined
as more than one ENL episode with the same characteristics as
acute single ENL. Chronic ENL is defined as an episode lasting
for more than six months. This could include single and multiple
episodes. Distinguishing and recognising these different types of
ENL will be useful in individual management and treatment of
ENL (Pocaterra 2006).
Erythema nodosum leprosum only occurs in people with border-
line lepromatous (BL) and lepromatous (LL) leprosy. These peo-
ple have high bacterial loads which increase the risk of ENL. The
percentage of people diagnosed with ENL differs between coun-
tries and studies. Countries in Asia and Brazil report high rates
of ENL. A study from India found an overall ENL prevalence of
24% (Pocaterra 2006) and a study from Brazil reported an ENL
rate of 31% among people on MB MDT treatment (Nery 1998).
Studies that look at BL and LL subgroups rather than the whole
MB leprosy group will give better estimations of ENL rates, be-
cause only these subgroups are at risk of developing ENL (Walker
2007). An Indian study found that almost 50% of people with
LL and 9% of people with BL had ENL (Pocaterra 2006), and
in a study from Ethiopia 12% of those with LL and 4% of those
with BL developed ENL (Saunderson 2000). Erythema nodosum
leprosum may occur before the start of treatment, but usually de-
velops within the first three years after starting multiple-drug ther-
apy (MDT). After completion of treatment, people may still have
episodes of ENL for several years, because they have persisting
mycobacterial antigens despite successful antibacterial treatment
(ILEP 2002; Naafs 2003a).
Causes and risk factors
Erythema nodosum leprosum is an immune-mediated complica-
tion of leprosy. It is caused partly by deposition of M. leprae anti-
gen and antibody complexes. These complexes circulate in the
blood and may precipitate in tissue, particularly on the wall of
small blood vessels, causing acute inflammation (vasculitis) and
release of tissue-damaging enzymes in any organ or tissue invaded
by the leprosy bacillus. In addition, the immune system activates
cells (macrophages and T cells) that attack and kill the bacte-
ria (Lockwood 1996; Naafs 2003b; Kahawita 2008). Risk fac-
tors for developing ENL are lepromatous classification, high bac-
terial loads, and being aged under 40 years (Manandhar 1999;
Saunderson 2000; Kumar 2004).
Impact
People who have ENL usually feel ill (general malaise, fever) and
many organs may be affected. Erythema nodosum leprosum is
often a recurrent or chronic condition and requires treatment for
a long period. Having repeated episodes of ill health, especially
in people who are in an economically active period in their lives
may cause a further burden. It may affect male fertility due to
inflammation of the testis. Women are affected by having fewer
treatment options in their childbearing years due to the side-ef-
fects of drugs such as thalidomide (Nery 1998; Saunderson 2000;
Pocaterra 2006). Leprosy has a far more negative image thanmany
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other diseases. Having visible signs of leprosy or side-effects from
treatment triggers discrimination and stigmatisation (Heijnders
2004; Rafferty 2005). The psychological impact of a chronic and
stigmatising condition may be profound.
Description of the intervention
Most therapies for ENL aim to control acute inflammation, reliev-
ing the pain and preventing further nerve damage or new episodes.
Several treatments are available for ENL.
How the intervention might work
The conventional treatment for mild ENL is rest and anti-inflam-
matory medication to control the acute inflammatory skin lesions
and fever. Aspirin is the most commonly used anti-inflammatory
drug, but indomethacin, chloroquine, and colchicine have been
tested as well. These different anti-inflammatory drugs have not
been formally compared in mild ENL and there is no data to
suggest that they are superior to aspirin (ILEP 1996; Lockwood
1996).
For severe ENL, prednisolone and clofazimine aremost commonly
used. Prednisolone usually acts rapidly by controlling the acute
inflammation and relieving the pain, fever, and other signs. The
starting dose should be the lowest possible to control ENL and
be gradually reduced. The schedule for reducing prednisolone de-
pends on the course of the disease. Erythema nodosum leprosum
is often recurrent or chronic and requires high-dose and prolonged
courses of prednisolone for the disease to be controlled. This in-
creases the risk of adverse events, such as hypertension or diabetes,
and steroid dependency (ILEP 1996; Lockwood 1996).
Clofazimine is considered a useful anti-inflammatory drug when
corticosteroids are contraindicated or need to be reduced (WHO).
However, treatment with clofazimine usually takes four to six
weeks to become active and the dose of clofazimine needed to con-
trol ENL is higher than the dose used in MDT (ILEP 1996). Dis-
advantages of continuous high doses of clofazimine are gastroin-
testinal symptoms (e.g. diarrhoea) and dark discolouration of the
skin. These skin changes usually develop within a few weeks after
starting clofazimine treatment and may take two or more years to
disappear (ILEP 1996; Lockwood 1996).
Another drug used to treat ENL is thalidomide. The effective-
ness of thalidomide in ENL is primarily due to its action on the
proflammatory cytokine TNF-α (tumour necrosis factor-α) but
other mechanisms may contribute to its anti-inflammatory effect
(Walker 2007). The seventhWHOExpertCommittee on Leprosy
considered thalidomide as an effective treatment of severe ENL,
and recommended restriction of thalidomide treatment tomale or
postmenopausal female patients only. Thalidomide should only be
given to women of childbearing age when comprehensive contra-
ceptive precautions can be taken, because its use may cause serious
birth defects when taken in early pregnancy (WHO 1998).
Other therapies have been tested, such as ciclosporin, pentox-
ifylline, oral zinc, and Mycobacterium w vaccination (Uyemura
1986; Zaheer 1993; Mahajan 1994; Nery 2000). New therapies
for other immune-mediated conditions seem promising. Exam-
ples are TNF-α antibody treatment, intravenous immunoglobu-
lin, and tenidap (Lockwood 1996). TNF-α antibody treatment
(infliximab) has been reported to be successful in the treatment
of a single case of recurrent ENL (Faber 2006). However, the per-
son relapsed and eventually required treatment with thalidomide
(Faber, personal communication). It is plausible that these thera-
pies may be effective for controlling ENL, but evidence from ran-
domised controlled trials is very limited.
Why it is important to do this review
Erythema nodosum leprosum is a serious immunological compli-
cation of leprosy. The complex mechanisms underlying ENL are
not yet fully understood, which makes treatment difficult. Corti-
costeroids, clofazimine, and thalidomide are the drugs of choice
for ENL, but all have drawbacks and the optimal regimen has not
been established. Alternative therapies have been tested, but it is
unclear if they are beneficial, or which one is preferable. The role
of newer treatments, such as TNF-α antibody treatment, intra-
venous immunoglobulin, and tenidap, is not known.
O B J E C T I V E S
To assess the effects of any therapy or treatment used in the man-
agement of ENL.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) of any design.
Types of participants
Anyone affected by leprosy with ENL, confirmed by appropri-
ate clinical features. The definition of ENL is: ’an inflammatory
condition, in which people develop crops of tender erythematous
subcutaneous skin lesions’. There may be accompanying neuritis,
iritis (inflammation of the iris), arthritis, orchitis (inflammation
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of the testis), dactylitis (inflammation of the fingers and toes),
lymphadenopathy, oedema, and fever. The skin signs are obliga-
tory; the nerve and general signs optional (Smith 2002; Van Brakel
2005).
Types of interventions
Any therapy for ENL, including:
(1) Systemic corticosteroids
• Oral therapies: prednisolone
• Intravenous therapies: betamethasone, methylprednisolone
(2) Systemic non-steroidal immunomodulatory therapies
• Immune modulators: thalidomide, ciclosporin,
pentoxifylline
• Anti-inflammatory therapies: clofazimine, aspirin,
chloroquine, colchicine, indomethacin
(3) Diverse therapies
• Oral zinc
• Mycobacterium w vaccine
The comparators were no treatment, placebo, usual care (e.g.
systemic corticosteroid with or without pentoxifylline), or an-
other listed therapy. We included trials which compared different
dosages of the same therapy or different routes of administration
(e.g. intravenous versus oral systemic corticosteroids).
Types of outcome measures
Primary outcomes
(a) The proportion of participants achieving remission of
skin lesions
Remission was defined as the absence of new tender erythematous
subcutaneous skin lesions at completion of the ENL therapy, as
assessed by a clinician.
Secondary outcomes
(a) The proportion of participants achieving remission of
inflammations at other sites
Remission was defined as the disappearance of inflammation as-
sociated with ENL at sites other than the skin (e.g. iritis, arthritis)
at completion of the ENL therapy, as assessed by a clinician.
(b) Investigator-assessed change in ENL severity
The change in ENL severity, compared to baseline, using a grading
scale as used in each of the studies.
(c) Time to next clinical episode of ENL
Time to next clinical episode of ENL was defined as the time
between the last dose of ENL treatment and appearance of new
signs of ENL reaction.
(d) Changes in quality of life
As assessed using a recognised instrument (generic, dermatology
specific, disease specific, or patient-generated index).
Timing of outcome assessment
We considered data that had been recorded for four weeks or less
from the start of treatment to reflect short-term benefit and these
were analysed separately from data that were recorded for more
than four weeks from the start of treatment, which we considered
to reflect the minimum time period to capture any longer-term
benefit.
The short-term assessment (one to four weeks) was considered the
primary endpoint, because the definite treatment effects should be
visible within the first few weeks. The medium-term assessment
(between four weeks and six months) was used as a secondary
endpoint. Assessments of more than six months after the start of
treatment were considered long-term outcomes.
Adverse outcomes
We were looking at a wide range of interventions and could
not pre-specify which were the most important/common adverse
events. Therefore we have documented the incidence and severity
of all recorded local and systemic adverse events, at any time point,
in all the included studies.
Economic data
Data relating to costs were not reported and we could not address
cost implications in the discussion due to lack of data.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Skin Group Specialised Register on
11th March 2009 using the following search terms: (leprosy and
type and 2) or lepromatous or lepra* or (erythema and nodosum)
or ’ENL’ or (leprosy and borderline) or leprosum.
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We searched the Cochrane Central Register of Controlled Trials
in The Cochrane Library (Issue 1, 2009) using the search strategy
in Appendix 1.
We searched MEDLINE (from 2003) on 11th March 2009 using
the search strategy in Appendix 2.
We searched EMBASE (from 2005) on 11th March 2009 using
the search strategy in Appendix 3.
The UKCochrane Centre (UKCC) has an ongoing project to sys-
tematically search MEDLINE and EMBASE for reports of trials
which are then included in the Cochrane Central Register of Con-
trolled Trials. Searching has currently been completed in MED-
LINE to 2003 and in EMBASE to 2005. Further searching has
been undertaken for this review by the Cochrane Skin Group to
cover the years that have not been searched by the UKCC.
We searched AMED (Allied and Complementary Medicine, from
1985) on 11th March 2009 using the search strategy Appendix 4.
We searched LILACS (Latin American and Caribbean Health Sci-
ence Information database, from 1982) on 11th March 2009 us-
ing the search strategy in Appendix 5.
We searched CINAHL (from 1980) on 17th March 2009 using
the search strategy in Appendix 6.
Ongoing Trials
We searched for ongoing trials in the following ongoing trials
registers on 17th March 2009 using the search terms ’leprosy’,
’erythema nodosum leprosum’ and ’type 2 reaction’:
The metaRegister of Controlled Trials www.controlled-trials.com
The U.S. National Institutes of Health Ongoing Trials Register
www.clinicaltrials.gov
The Australian and New Zealand Clinical Trials Registry
www.anzctr.org.au
TheWorldHealthOrganization International Clinical Trials Reg-
istry Platform www.who.int/trialsearch
The Ongoing Skin Trials register www.nottingham.ac.uk/
ongoingskintrials
Searching other resources
Grey literature
We checked the conference proceeding from the International
Leprosy Congress (2008) for RCTs and where appropriate the trial
authors were contacted for further information.
Reference lists
We checked the references of the included studies, but did not
identify any further trials.
Correspondence
Where possible we corresponded with trial authors of studies less
than 15 years old about unpublished and ongoing trials. We con-
tacted a technical consultant at the American Leprosy Missions in
Brazil for reports of trials from Brazil.
Adverse effects
Wedid not do a separate search for adverse events, but we searched
within the included studies.
Language restrictions
There were no language restrictions when we searched for publi-
cations. We sought translations of papers in languages other than
English. Taixiang Wu interpreted a paper in Chinese, and Brenda
Gomes and Marcos Virmond interpreted papers in Portuguese.
Data collection and analysis
Selection of studies
Two authors (NvV, JHR) checked the titles and abstracts identified
from the searches. If it was clear that the study did not refer to
a randomised controlled trial on erythema nodosum leprosum, it
was excluded. If it was unclear, then the full text of the study was
obtained for independent assessment by two authors (NvV, JHR).
The authors decided which trials fitted the inclusion criteria. Any
disagreement was resolved by discussion between the authors. It
was not necessary to refer to a third author. We recorded excluded
studies and reasons for exclusion in the Characteristics of excluded
studies table.
Data extraction and management
One author (NvV) entered data onto a data extraction form and a
second author (JHR) checked the data. The authors (NvV, JHR)
discussed discrepancies between themselves.Missing data were ob-
tained from trial authors where possible. One author (NvV) en-
tered data into RevMan. The authors were not blinded to the
names of trial authors, journals, or institutions.
For the participants’ and investigators’ global assessments of im-
provement, the authors translated reported changes in ENL sever-
ity into the proportion of participants with improvement greater
than minimal. By improvement greater than minimal we meant
anything greater than the first category of improvement on a Lik-
ert scale, or greater than 50% improvement from baseline on a
continuous scale. For the purpose of calculating clinical efficacy,
we regarded categories relating to greater than minimal improve-
ment as a treatment success.
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All other outcomes were expressed as the actual or percentage
change from baseline.
Assessment of risk of bias in included studies
The quality assessment included an evaluation of the following
components for each included study, since there is some evidence
that these are associated with biased estimates of treatment effect
(Juni 2001):
(a) the method of generation of the randomisation sequence;
(b) the method of allocation concealment - it was considered ’ad-
equate’ if the assignment could not be foreseen;
(c)whowas blinded/not blinded (participants, clinicians, outcome
assessors);
(d) howmany participants were lost to follow-up in each arm (split
into postrandomisation exclusion and later losses if possible) and
whether participants were analysed in the groups to which they
were originally randomised (intention-to-treat principle).
In addition, assessment was made of the following:
(e) degree of certainty that participants have ENL;
(f ) baseline comparison for age, sex, duration, and severity of ENL;
(g) whether outcome measures were described adequately.
The information is recorded in the risk of bias table under
Characteristics of included studies.
Measures of treatment effect
Dichotomous data
We expressed the results as risk ratio (RR) and 95% confidence
intervals (CI) for dichotomous outcomes.
Continuous data
We expressed the results as differences in means (MD) and 95%
CI for continuous outcomes. We did not use a standardised mean
difference (SMD) since no continuous outcome measures could
be combined.
Time-to-event data
We had no time-to-event data to summarise the log hazard ratio
and 95% CI.
Unit of analysis issues
Cross-over trials
We analysed cross-over trials using data from the first phase only,
but could not pool with parallel design studies due to lack of
comparable studies or differences in timingof outcome assessment.
Studies with multiple treatment groups
Where there were multiple intervention groups within a trial, we
made pairwise comparisons of similar ENL interventions or ENL
active components versus no treatment, placebo, or another ENL
intervention.
Other
We did not find any internally controlled trials. We excluded non-
randomised controlled studies from the analyses but these were
commented on in the Discussion section.
Dealing with missing data
We were not able to conduct an intention-to-treat analysis when
participant drop-out led tomissing data due to lack of information
from trial authors.We contacted trial authors of studies less than15
years old to provide missing statistics such as standard deviations,
but they failed to respond or provide us with the missing data.
Assessment of heterogeneity
We did not assess statistical heterogeneity using the I2 statistic,
because there were no studies to be pooled.
Assessment of reporting biases
We did not perform funnel plots, because there were fewer than
ten poolable studies.
Data synthesis
We did not perform a meta-analysis to calculate a weighted treat-
ment effect across trials, using a random-effects model, because
there were no studies with a similar type of ENL intervention or
a similar active component. Instead, we summarised the data for
each trial.
Subgroup analysis and investigation of heterogeneity
We did not perform further subgroup analysis due to lack of data
on different subgroups. The groups were different severity of ENL
(mild or severe) and different duration of ENL (single acute, mul-
tiple acute, or chronic).
Sensitivity analysis
We did not perform sensitivity analyses examining the effects of
excluding study subgroups, e.g. those studies with low method-
ological quality, since no meta-analyses were performed.
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Other
Where there was uncertainty, we contacted the trial authors for
clarification. A consumer was part of the review team to ensure
the relevance and readability of the final review.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We found 269 citations to potentially relevant trials from the elec-
tronic searches. Eight potentially eligible studies were found from
references of included trials and reviews. Correspondence with au-
thors and other persons and searching of grey literature revealed
one potentially relevant trial. We identified 48 possible studies, of
which 13 were RCTs. The search of the Ongoing Trial Registers
revealed one ongoing trial.
Included studies
We included 13 trials with 445 participants in this review and these
are described in the Characteristics of included studies table. Ten
studies were published between 1969 and 1985 and three studies
between 2002 and 2007. The follow-up period varied from 7 days
to 60 weeks in 13 trials and was unclear in 1 trial (Karat 1969).
Design
Three trials had a cross-over design (Pearson 1969; Helmy 1971;
Waters 1971) and 10 trials had a parallel group design, of which
1 trial had 4 parallel groups (Karat 1969).
Sample sizes
The studies involved sample sizes between 9 and 92 participants.
Two studies randomised and evaluated ENL reactions of partici-
pants (Iyer 1971; Sheskin 1969).
Setting
Twelve studies were done in single centres in Brazil, India,
Malaysia, Philippines, Singapore, and Venezuela. One study was
conducted in multiple centres in India, Mali, Somalia, and Spain
(Iyer 1971).
Participants
The age range of participants in 8 studies was 14 to 69 years, 5
studies did not report information on the age of the participants.
Five studies includedbothmales and females, four studies included
only males, and four studies did not report this information. The
duration of ENL reactions varied from 0 to 12.5 years in 8 trials,
and 5 trials did not report this information. The severity of reac-
tions ranged from mild to severe and was reported in eight trials.
Interventions
The included studies examined several interventions.
Systemic corticosteroids:
• infusion of betamethasone in 5% dextrose versus infusion
of 5% dextrose (Girdhar 2002; parallel group).
Systemic non-steroidal immunomodulatory therapies:
• thalidomide versus placebo (Pearson 1969; Waters 1971:
cross-over; Sheskin 1969: parallel group);
• thalidomide versus acetylsalicylic acid (Iyer 1971; parallel
group);
• 100 mg thalidomide regimen versus 300 mg thalidomide
regimen (Villahermosa 2005; parallel group);
• pentoxifylline versus thalidomide (Sales 2007; parallel
group);
• clofazimine versus placebo (Helmy 1971; cross-over);
• clofazimine versus thalidomide (Iyer 1976; parallel group);
• clofazimine versus prednisolone (Karat 1970; parallel
group);
• indomethacin versus prednisolone (Ing 1969; parallel
group);
• indomethacin versus chloroquine versus prednisolone
versus aspirin (Karat 1969; parallel group);
• levamisole versus placebo (Arora 1985; parallel group).
Diverse therapies:
• no trials assessing any other therapies were found.
Cointerventionswere reported in 11 trials. These included iron for
those with anaemia, anti-leprosy treatments (dapsone or MDT),
analgesics (e.g. paracetamol, stibophen), steroids, and diuretics for
treating oedema.
Outcomes
The primary outcome of remission of skin lesions, measured as the
absence of new tender erythematous subcutaneous skin lesions at
completion of the ENL therapy, was not explicitly reported in any
of the trials. Two trials defined treatment success or improvement
including the absence of new ENL lesions (Sheskin 1969; Karat
1970). Three studies reported the resolution of existing skin le-
sions (Ing 1969; Villahermosa 2005; Sales 2007), and one study
reported the number of participants with no further reaction after
the first treatment regimen (Iyer 1971).
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The secondary outcome of remission of inflammation at other
sites was not explicitly reported in any of the trials. Seven trials
used different grading scales or scores to assess ENL severity (Karat
1969; Pearson 1969; Helmy 1971; Waters 1971; Arora 1985;
Girdhar 2002; Villahermosa 2005). The secondary outcome of
time to next clinical episode was not reported in any of the trials,
but four trialsmentioned recurrence rates of reactions (Karat 1969;
Karat 1970; Iyer 1976; Villahermosa 2005). None of the studies
measured changes in quality of life.
Six trials recorded data only for four weeks or less from the start of
treatment, reflecting short-term benefit (Ing 1969; Sheskin 1969;
Helmy1971; Iyer 1971;Waters 1971; Sales 2007). Three trials had
the outcome assessment atmedium-term, ranging from four weeks
to six months from the start of treatment (Pearson 1969; Karat
1970; Arora 1985). One trial assessed long-term benefit, more
than six months after treatment (Girdhar 2002). One trial assessed
both short-term and medium-term (Villahermosa 2005), and one
trial both medium-term and long-term (Iyer 1976). The timing
of outcome assessment was unclear in one trial (Karat 1969).
Adverse effects were not reported in three trials (Arora 1985;
Helmy 1971; Iyer 1976).
There was great diversity (or heterogeneity) between interventions
and methods used to measure outcomes in the trials. None of the
studies used similar interventions and comparisons which could
be pooled.
Excluded studies
We excluded 35 studies and their details can be found in the
Characteristics of excluded studies table. Of these 35 studies, 21
were not RCTs, 2 were excluded as they did randomisation by al-
ternation, 10 did not have ENL as inclusion criterion but included
participants with lepromatous leprosy in general, 1 was a duplicate
study, and 1 was excluded because it described only intake results
and was not completed.
Ongoing studies
We found one ongoing randomised, single-blind trial examining
montelukast in ENL reaction, compared to prednisolone. Enroll-
ment started in December 2006 and took 18 months. Outcome
assessment was scheduled 24 weeks after starting treatment.
Risk of bias in included studies
The Collaboration’s recommended tool for assessing risk of bias
was used (Higgins 2008), the methodological quality of the trials
was generally poor. Since no meta-analyses were performed, sensi-
tivity analysis based onmethodological quality was not performed.
Three trials had a cross-over design (Pearson 1969; Helmy 1971;
Waters 1971). The main concerns associated with cross-over trials
are: (i) whether the cross-over design is suitable; (ii) whether there
is a carry-over effect; (iii) whether only first period data are avail-
able; (iv) incorrect analysis; and (v) comparability of results with
those from parallel-group trials. None of the trials had a wash-out
period between the two interventions, which might have caused
a possible carry-over effect, especially in the trial assessing clofaz-
imine that can persist in the body for a long time. We analysed
these trials using data from the first phase only if these were avail-
able to overcome these concerns.
Two trials evaluated reactions of participants (Sheskin 1969; Iyer
1971). Participants received up to four treatment regimens for
each reaction during the trials. This may have led to an over-
estimate of the effect because the within-patient variance between
outcomes of the same person may be smaller than the between-
patient variance of outcomes between individuals. We used only
data of the first randomised treatment if these were available to
overcome this concern.
Allocation
None of the trials were clear on how randomisation lists were
generated. In two of the trials, the trial authors have clearly re-
ported that concealment of allocation was adequate; both studies
had the medication pre-prepared by a drug company (Iyer 1971;
Villahermosa 2005).
Blinding
Blinding of outcome assessment was attempted for most of the
trials. However, the method as to how this was done was gener-
ally unclear and poorly described. None of the studies clearly de-
scribed who (the participants, clinicians, and outcome assessors)
was blinded. One trial was an open trial (Iyer 1976): this was a
trial with clofazimine, which is known to give skin discolouration.
Incomplete outcome data
Information about incomplete outcome data was generally not
reported and participant loss to follow-up ranged between 0%
and 33%. Seven trials did not report information on incomplete
outcome data, but if accepting no mention in the text and no
signs of attrition in tables, as a 100% follow-up, all of these trials
had a follow-up rate of 100% (Karat 1969; Sheskin 1969; Karat
1970; Iyer 1971; Waters 1971; Iyer 1976; Arora 1985). Two trials
with missing outcome data performed intention-to-treat analysis
(Pearson 1969; Sales 2007). Two trials (Ing 1969; Girdhar 2002)
had participant losses (1/30 participants and 1/10 participants re-
spectively), but it was not clear as to whether intention-to-treat
analysis was done. Two trials (Helmy 1971; Villahermosa 2005)
with incomplete outcome data (5/15 participants and 1/22 partic-
ipants respectively) did not perform an intention-to-treat analysis.
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Selective reporting
Six trials did not perform a statistical analysis, but only described
the results (Ing 1969; Pearson 1969; Helmy 1971; Iyer 1971;
Waters 1971; Iyer 1976). One study (Ing 1969) reported in the
summary that “indomethacin is effective in treating only mild and
moderate cases of ENL”. The summary of one study (Waters 1971)
concluded that “nine of the ten participants showed a very signif-
icant reduction in steroid requirement”. Another study (Pearson
1969) summarised that “thalidomide was superior to a placebo”.
None of these studies provided sufficient evidence (e.g. significant
test values) to support these claims.
Other potential sources of bias
Certainty of diagnosis
Five studies specified erythema nodosum leprosum (ENL) in
their inclusion criteria (Sheskin 1969; Karat 1970; Iyer 1971;
Villahermosa 2005; Sales 2007).Most other studies did not define
ENL, but did mention it under the inclusion criteria.
Baseline comparison for age, sex, duration and severity of
ENL
Five studies did not provide data for baseline comparison (Karat
1969; Pearson 1969;Helmy 1971; Iyer 1971; Girdhar 2002). Five
studies reported some baseline data, but it was unclear whether
groups were similar at baseline (Ing 1969; Sheskin 1969; Waters
1971; Iyer 1976; Arora 1985). Two studies reported only two (age
and sex) (Sales 2007) or three (age, sex, and duration of ENL)
(Villahermosa 2005) of the characteristics being similar in both
groups. In one study, all baseline characteristics (age, sex, duration,
and severity of ENL) were similar in both groups (Karat 1970).
Explicit outcome measures
Six studies did not clearly describe outcomemeasures (Karat 1969;
Pearson 1969; Helmy 1971; Iyer 1971; Iyer 1976; Arora 1985).
The other studies did explicitly mention outcome measures, such
as change in ENL severity, improvement, and treatment success.
Effects of interventions
Please see table of Characteristics of included studies. Subgroup
analysis was not performed as there were no appropriate studies
to pool. Of the 13 studies included, none compared the same
interventions or had comparable outcomes. We did not find any
trials assessing therapies as listed under diverse therapies.
Timing of outcome assessment
Results have been grouped according to the timing of outcome
assessment: short-term (one to four weeks), medium-term (be-
tween four weeks and six months), and long-term (more than six
months).
Economic data
None of the trials reported economic outcome data.
Primary outcome measure
(a) The proportion of participants achieving remission of
skin lesions
None of the studies reported the absence of new skin lesions at
the end of therapy. Two studies had outcome measures that were
considered to reflect our primary outcome measure. Karat 1970
reported treatment success, including absence of new ENL lesions,
and Sheskin 1969 reported improvement, including absence of
new ENL lesions, but did not provide separate data of the first ran-
domised treatment regimen for comparison. Five studies report-
ing differing definitions of remission of skin lesions. One study
reported the number of participants with no further reaction after
the first treatment regimen, implying absence of new ENL skin
lesions (Iyer 1971). Three studies reported the resolution of exist-
ing skin lesions (Ing 1969; Villahermosa 2005; Sales 2007).
Systemic corticosteroids
Remission of skin lesions was not reported for any systemic corti-
costeroid intervention.
Systemic non-steroidal immunomodulatory therapies
Short-term:
Significantly more participants who received thalidomide treat-
ment had no further reaction after seven days, requiring a sec-
ond treatment regimen, compared to those receiving acetylsalicylic
acid (aspirin) treatment (RR 2.43; 95% CI 1.28 to 4.59; n=92;
Analysis 1.1) (Iyer 1971). No significant difference in resolution
of existing inflamed ENL nodules was found between the 100 mg
thalidomide regimen and the 300 mg thalidomide regimen after
seven days (RR 1.33; 95% CI 0.64 to 2.79; n=22; Analysis 2.1)
(Villahermosa 2005). No significant difference in the resolution
of existing inflamed ENL skin nodules was observed between pen-
toxifylline and thalidomide after 30 days of treatment (RR 1.05;
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95%CI 0.74 to 1.49; n=25; Analysis 3.1) (Sales 2007). No signifi-
cant difference in remission of existing ENL lesions was found be-
tween indomethacin and prednisolone after four weeks (RR 2.33;
95% CI 0.76 to 7.13; n=30; Analysis 6.1) (Ing 1969).
Medium-term:
One participant, who had received the 300 mg thalidomide regi-
men, had a successful taper, defined as a complete response after
seven days and lack of new acutely inflamed lesions during the six-
week taper and for at least two months after stopping thalidomide
(Villahermosa 2005). Significantly more treatment successes were
observed in the clofazimine group compared to the prednisolone
group at the end of 12 weeks of treatment (RR 3.67; 95% CI 1.36
to 9.91; n=24; Analysis 4.1) (Karat 1970).
Secondary outcome measures
(a) The proportion of participants achieving remission of
inflammation at other sites
Remission of inflammations at other sites was not reported in any
of the studies. In Iyer 1971, the data was reported inadequately
as there was no separate data from the first randomised treatment
regimen.
(b) Investigator-assessed change in ENL severity
One study used a global assessment score to assess for changes
in ENL symptoms (anorexia, arthralgias, chills, malaise, neuritis,
orchitis, and fever) (Villahermosa 2005).One study used a grading
scale (0 to 3) to assess changes in ENL severity, with higher grades
indicating more severe ENL (Arora 1985). One study (Pearson
1969) used an ENL severity score, but did not provide individual
participant data or means and standard deviations for comparison.
Two studies assessed change inENL severity usingdifferent scoring
methods, but provided only sum scores of the weekly scores over
the four-week trial period (Helmy 1971;Waters 1971). One study
assessed the frequency and severity of ENL, but did not provide
data or significant test values for comparison (Girdhar 2002). One
study reported control of reaction, but it was unclear how control
was defined (Karat 1969). It was unclear whether any of the scales
used had been formally validated.
Systemic corticosteroids
Change in ENL severity was not reported for any systemic corti-
costeroid interventions.
Systemic non-steroidal immunomodulatory therapies
Short-term:
No significant difference in improvement (becoming asymp-
tomatic) was found between the 100 mg thalidomide regimen and
the 300mg thalidomide regimen after seven days of treatment (RR
1.67; 95% CI 0.85 to 3.26; n=22; Analysis 2.2) (Villahermosa
2005).
Medium-term:
No significant difference in improvement (change from grade 3 to
grade 1 or 0) was observed between levamisole and placebo after
three months (RR 0.95; 95% CI 0.36 to 2.49; n=12; Analysis 9.1)
(Arora 1985). No significant difference in control of reaction was
found between indomethacin and chloroquine (RR 0.95; 95% CI
0.52 to 1.74; n=23; Analysis 7.1), prednisolone (RR 0.65; 95%
CI 0.41 to 1.02; n=24; Analysis 6.2) or aspirin (RR 0.89; 95%
CI 0.51 to 1.55; n=25; Analysis 8.1) respectively. The duration of
the trial and timing of outcome assessment was unclear; the paper
stated both a trial period of 90 days and of 12 months (Karat
1969).
(c) Time to next clinical episode of ENL
Time to next clinical episode of ENL was not reported in any
of the studies. Four studies reported differing definitions of time
to next clinical episode of ENL. One study reported recurrence
of new lesions by week seven in participants who had achieved
remission of existing ENL skin lesions at the end of the first week (
Villahermosa 2005).One study reported relapse of ENLwithin 52
weeks after treatment (Iyer 1976). Two studies reported recurrence
of ENL by the end of the trial period in participants whose initial
reaction was controlled in this same period (Karat 1969; Karat
1970).
Systemic corticosteroids
Time to next clinical episode of ENL was not reported for any
systemic corticosteroid interventions.
Systemic non-steroidal immunomodulatory therapies
Medium-term:
No significant difference in recurrence of new lesions after seven
weeks was observed between the 100 mg thalidomide regimen
and the 300 mg thalidomide regimen (RR 3.75; 95% CI 0.62 to
11Interventions for erythema nodosum leprosum (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
22.64; n=13; Analysis 2.3) (Villahermosa 2005). No significant
difference in recurrence of ENL was found between clofazimine
and prednisolone at the end of 12 weeks (RR 0.14; 95% CI 0.02
to 1.04; n=14; Analysis 4.2) (Karat 1970).
Long-term:
Results showed significantly less participants with relapse of ENL
in the clofazimine group compared to the thalidomide group
within 52 weeks after treatment (RR 0.08; 95% CI 0.01 to 0.56;
n=72; Analysis 5.1) (Iyer 1976). No significant difference in re-
currence of ENLwas observed between indomethacin and chloro-
quine (RR 1.14; 95% CI 0.44 to 2.94; n=15; Analysis 7.2), pred-
nisolone (RR 0.83; 95% CI 0.40 to 1.72; n=20; Analysis 6.3) or
aspirin (RR 0.82; 95% CI 0.38 to 1.74; n=17; Analysis 8.2) re-
spectively at the end of the trial period (90 days or 12 months)
(Karat 1969).
(d) Changes in quality of life
None of the trials reported changes in quality of life.
Adverse events
Three trials did not report on adverse events (Helmy 1971; Iyer
1976; Arora 1985). The other trials did provide information about
adverse events, but often the number of participants with any
adverse events in both groups was unclear.
Systemic corticosteroids
Minor adverse events not requiring withdrawal from treatment
(swelling of the face, ’buffalo hump’, striae distensae, and acne)
were more often reported in participants who received intravenous
dextrose alone and oral steroids per their need to control ENL
(control group) compared to those who received intravenous be-
tamethasone in 5% dextrose, but the number of participants with
adverse events in each group was not given (Girdhar 2002).
Systemic non-steroidal immunomodulatory therapies
Withdrawals from thalidomide treatment were caused by intesti-
nal obstruction (1/12 participants) (Pearson 1969), and worsen-
ing of ENL symptoms (3/22 participants) (Villahermosa 2005).
Minor adverse events not requiring withdrawal from thalidomide
treatment (e.g. mild dermatitis, constipation, nausea, drowsiness,
headache, insomnia, dizziness, dryness) were reported, but data for
comparison was often unclear or lacking (Pearson 1969; Sheskin
1969; Iyer 1971; Waters 1971; Sales 2007). Significantly less par-
ticipants in the 100 mg thalidomide regimen group reported any
mild to moderate adverse events compared to those in the 300 mg
thalidomide regimen group during the seven-week regimen (RR
0.46; 95% CI 0.23 to 0.93; n=22; Analysis 2.4) (Villahermosa
2005).Withdrawals from pentoxifylline were due to gastrointesti-
nal intolerance to the drug (1/24 participants) and fever and con-
tinuing lesion inflammation (3/24 participants). Adverse events
not requiring withdrawal from pentoxifylline treatment (e.g. gas-
trointestinal complaints, nausea) were reported in 2/24 partici-
pants (Sales 2007). Significantly more participants who received
clofazimine had minor adverse events compared to those who
received prednisolone (RR 1.92; 95% CI 1.10 to 3.35; n=24;
Analysis 4.3). In the clofazimine group all participants had red/
black pigmentation. No withdrawals from either clofazimine or
prednisolone treatment were reported (Karat 1970). Withdrawal
from indomethacin treatment was due to deterioration of ENL
(1/16 participants). Minor adverse events (e.g. nausea, dizziness,
insomnia) were more frequently reported in participants who re-
ceived indomethacin (9 events) compared to those who received
prednisolone (1 event) (Ing 1969). No significant differences in
minor adverse events (e.g. abdominal pain, nausea, headache) were
observed between indomethacin and chloroquine (RR 1.09; 95%
CI 0.57 to 2.10; n=23; Analysis 7.3), prednisolone (RR 0.92; 95%
CI 0.52 to 1.63; n=24; Analysis 6.4) and aspirin (RR 2.23; 95%
CI 0.87 to 5.71; n=25; Analysis 8.3) respectively (Karat 1969).
D I S C U S S I O N
Summary of main results
There are no good controlled trial data on the optimum treatment
for controlling the acute phase of ENL. Our review included 13
randomised controlled trials involving 445 participants, and as-
sessed the effects of betamethasone, thalidomide, pentoxifylline,
clofazimine, indomethacin, and levamisole in the management
of ENL. One trial showed thalidomide treatment to be superior
to acetylsalicylic acid treatment (less new reactions requiring fur-
ther treatment) (Iyer 1971) in the short-term control of ENL.
Two trials showed significant longer-term benefits of clofazimine
treatment compared to thalidomide (fewer recurrences) or pred-
nisolone (more treatment successes) respectively (Karat 1970; Iyer
1976). Mild to moderate adverse events were significantly higher
in participants taking a 300 mg versus 100 mg dose of thalido-
mide (Villahermosa 2005) and in participants taking clofazimine
compared with prednisolone (Karat 1970).
The results should be considered with caution, due to method-
ological shortcomings. Data extraction of the study of Iyer 1971
was limited to the results of the first randomised treatment regi-
men to avoid having more than one outcome per participant in
the analysis. In the study of Iyer 1976 participants continued on a
maintenance dose of either 100 mg clofazimine or 50 mg thalido-
mide daily during the year after therapy. The study found signif-
icantly less recurrences of ENL in the group who received clo-
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fazimine therapy and this effect may be due to the persistence of
clofazimine in the body over a longer period of time. Karat 1970
tapered the dose of prednisolone (starting at 30 mg daily and ta-
pered off to 5 mg daily), while the dose of clofazimine (300 mg
daily) remained the same during the 12-week treatment.
Overall completeness and applicability of
evidence
The studies identified were not sufficient to address all of the ob-
jectives of the review. Two studies had outcome measures that
were considered to reflect our primary outcome measure (Sheskin
1969; Karat 1970). Three studies assessed the disappearance of
existing ENL skin lesions rather than the absence of new ENL skin
lesions at the end of the therapy (Ing 1969; Villahermosa 2005;
Sales 2007), and one study reported no further reactions after the
first treatment regimen (Iyer 1971). None of the studies reported
adequately on the secondary outcome measure: remission of in-
flammation at other sites upon completion of the ENL therapy,
as assessed by a clinician. Seven studies assessed changes in ENL
severity using a self-defined definition, scale, or score (Karat 1969;
Pearson 1969; Helmy 1971; Waters 1971; Arora 1985; Girdhar
2002;Villahermosa2005).None of the studies reported on the sec-
ondary outcome or time to next clinical episode, but four studies
recorded recurrences of ENL in participants whose initial reaction
was controlled (Karat 1969; Karat 1970; Iyer 1976; Villahermosa
2005). Adverse eventswere reported in all but three studies (Helmy
1971; Iyer 1976; Arora 1985). None of the studies assessed the
effect of the intervention on quality of life of participants. The
studies did not provide separate data for different subgroups, such
as disease severity (mild or severe) or duration (single acute, multi-
ple acute, or chronic), while this could have given useful informa-
tion on effectiveness of treatment for different types of ENL. The
results of the studies do not allow any robust conclusion regarding
the general applicability of any of the interventions tested.
Quality of the evidence
The quality of trials was generally poor, especially in studies pub-
lished more than 20 years ago, due to the lack of clear reporting of
methods, data, and the allocation process.Most of the studies were
too small (10 to 92 participants) to identify important differences
even if they existed. Three studies had a cross-over design which is
associated with increased risk of bias (Pearson 1969; Helmy 1971;
Waters 1971). We therefore considered only the first phase treat-
ment. Two studies used more than one outcome of individual par-
ticipants in the analysis (Sheskin 1969; Iyer 1971). This may have
led to an over-estimate of the effect because the within-patient
variance between outcomes of the same person may be smaller
than the between-patient variance of outcomes between individ-
uals. We used only data of the first randomised treatment to over-
come this concern and these were only available for the trial of Iyer
1971. Most of the trials reported comedication, which may have
diluted the effect of the intervention tested in the studies. Most
of the studies were not clear as to how allocation sequences were
generated or how allocation was concealed. Blinding, especially of
the outcome assessor, was not described at all or unclear. Trials as-
sessing clofazimine were unblinded the moment skin discoloura-
tion appeared. This might have biased the outcome assessments.
Six studies reported incomplete outcome data, but only two of
those performed an intention-to-treat analysis. Baseline data were
poorly reported and absent in five studies. Adverse effects were
often reported inadequately, limiting comparisons between exper-
imental and control groups.
Potential biases in the review process
The search process was elaborate and to our knowledge no other
randomised controlled trials were available for this review. It is
possible that not all relevant studies have been included in this
review, and that we failed to find some unpublished trials. We
contacted several people, but did not identify any new trials. The
quality of reporting was generally poor and this may have led to
misunderstandings during the critical appraisal of the studies. We
contacted authors of studies less than 15 years old, but had poor
response to requests for additional information. We were unable
to assess for publication bias as there were not enough studies to
perform a funnel plot. Most studies were small and showed no
significant effect and we considered publication bias in this case
not very likely. Some studies, assessing interventions for people
with lepromatous leprosy and containing potentially useful data,
had to be excluded because no separate results for people with
ENL were reported.
Agreements and disagreements with other
studies or reviews
A few systematic reviews on interventions for ENL have been
found, but these focused on thalidomide and included non-ran-
domised studies (Penna 2005; Walker 2007). These reviews con-
cluded that although beneficial effects of thalidomide treatment
were found, the evidence is limited due to methodological dif-
ferences between studies and the use of thalidomide is restricted
because of possible serious adverse effects such as teratogenicity,
neuropathy, and thromboembolisms.
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Implications for practice
There is some evidence of benefit for thalidomide and clofazimine,
but generally we found insufficient evidence to make any firm
recommendations on the use of any of the interventions tested for
management of ENL and included in this review. This does not
mean they do not work, because the studies were generally of poor
quality and small-sized.
Treatment with thalidomide showed a significant benefit com-
pared to acetylsalicylic acid (aspirin). Clofazimine treatment was
superior to prednisolone and thalidomide. Current guidelines for
the management of ENL are given by bodies such as the World
Health Organization (WHO) and the International Federation
of Anti-Leprosy Associations (ILEP), but these guidelines are not
supported by evidence from randomised controlled trials and are
developed from practice.
Most of the studies reported adverse effects of treatment. Mild
to moderate adverse events were significantly higher in partici-
pants taking a 300 mg versus 100 mg dose of thalidomide and in
participants taking clofazimine compared with prednisolone. In
only a few instances was withdrawal from treatment required, but
it was not always clear whether this was due to treatment or for
another reason. Adverse effects of commonly used drugs, such as
prednisolone, clofazimine, and thalidomide are well-documented
and should be kept in mind when prescribing drugs for ENL.
Implications for research
The 13 trials included in this review were generally of poor
methodological quality and have mostly been of short duration.
A wide range of interventions were assessed, one trial evaluated
betamethasone, five trials thalidomide, one trial pentoxifylline,
three trials clofazimine, two trials indomethacin, and one trial lev-
amisole.
It was often unclear what the duration and severity of ENL was
before the starting of treatment. Future studies should have clearer
case definitions for ENL and we recommend that different du-
rations of ENL (single acute episode, multiple acute episode, or
chronic) and different severity of ENL (mild or severe) be distin-
guished, as such subgroups may need different management of
ENL.
Erythema nodosum leprosum is a complicated disease known for
its unpredictablility, its variable severity and duration, and its often
chronic and recurrent nature. Although most agents may work
similarly for controlling the acute symptoms of ENL, prevention
of recurrences is far more difficult.
There is a need for good quality studies which follow the current
standards for design and reporting of randomised controlled trials,
and for large multi-centre studies to ensure that enough partici-
pants are enrolled.
None of the studies investigated whether the interventions im-
proved quality of life of participants and only a few examined the
long-term effects of interventions. There is a need for clearly de-
fined outcome measures, both in the short-term and longer-term.
We would recommend that future studies include outcomes such
as absence of new tender erythematous subcutaneous skin lesions
at completion of the ENL therapy, disappearance of inflammation
associated with ENL at sites other than the skin (such as iritis and
arthritis) at completion of the ENL therapy, as well as time to next
clinical episode of ENL after completion of treatment, and quality
of life measures.
It is recommended that internationally recognised and validated
severity scales be developed so that results from different countries
can be compared.
A trial comparing directly prednisolone and thalidomide has never
been done, and is urgently needed.
Future studies should aim to assess the efficacy, safety, and optimal
regimens of prednisolone and thalidomide for severe ENL and
clofazimine for mild ENL as well as other potentially beneficial
therapies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arora 1985
Methods Design: parallel group
Participants Setting: single centre, hospital, India
Incl: participants with ENL
Excl: not stated
M/F: 11/1
Age: 14 to 55
Duration: 0 to 7 years
Severity: severe
Randomised: 12 participants
Evaluable: 12 participants
Unit of analysis: individual
Interventions Experimental group (n=5): levamisole capsules (150 mg daily) on 3 consecutive days
repeating every fortnight for 3 months
Control group (n=7): placebo capsules (dose unknown, daily) on 3 consecutive days
repeating every fortnight for 3 months
Other therapy: iron for anaemic participants
Outcomes Improvement, defined as complete recovery from reaction, after 3 months
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Unclear risk Unclear, though states ’coding of drugs was done by other per-
son and decoding at end of study’
Blinding?
All outcomes
Unclear risk Unclear who were blinded, though states trial was double-blind
Incomplete outcome data addressed?
All outcomes
Unclear risk No mention of attrition in text or tables, suggesting 100%
follow-up
Free of selective reporting? Low risk
Free of other bias? Unclear risk Not clear as towhether groupswere similar at baseline; outcome
measures not well-described
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Girdhar 2002
Methods Design: parallel group
Participants Setting: single centre, leprosy centre, India
Incl: lepromatous leprosy with recurrent ENL and on steroids for > 6 months
Excl: not stated
M/F: not stated
Age: not stated
Duration: not stated
Severity: not stated
Randomised: 10 participants
Evaluable: 9 participants (1 lost to follow-up)
Unit of analysis: individual
Interventions Experimental group (n=4): infusion of betamethasone in 5% dextrose daily for 3 days
every 4 weeks for 6 months
Control group (n=5): infusion of 5% dextrose daily for 3 days every 4weeks for 6months
Other therapy: MDT with 100 mg clofazimine daily for all participants; oral steroids as
per need to control ENL for participants in control group
Outcomes Change in severity and frequency of ENL 6 months after end of treatment
Steroid requirement
Side-effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Unclear risk No information provided
Incomplete outcome data addressed?
All outcomes
Unclear risk No information provided
Free of selective reporting? Low risk
Free of other bias? Unclear risk No information about baseline characteristics of both groups
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Helmy 1971
Methods Design: cross-over
Participants Setting: single centre, leprosy centre, Malaysia
Incl: not stated, though included were lepromatous or indefinite leprosy withmoderately
severe ENL
Excl: not stated
M/F: 10/5
Age: 17 to 67
Duration: 6 months to 2 years
Severity: moderately severe ENL
Randomised: 15 participants
Evaluable: 10 participants (5 lost to follow-up)
Unit of analysis: individual
Interventions Group A (n=3): clofazimine capsules (100 mg 3 times daily) in weeks 1 to 4, followed
by placebo capsules (dose unknown, 3 times daily) in weeks 5 to 8
Group B (n=7): placebo capsules (100 mg 3 times daily) in weeks 1 to 4, followed by
clofazimine capsules (dose unknown, 3 times daily) in weeks 5 to 8
Other therapy: dapsone (100 mg 2 times daily); stibophen if needed; paracetamol issued
twice weekly to be taken freely
Outcomes Severity score of ENL
Notes The trial consisted of a first control period (2 weeks), first trial period (4 weeks), second
trial period (4 weeks), second control period (4 weeks)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Unclear risk Unclear, though states “key of drug allocation was kept in sealed
envelope and opened only after analysis of the results”
Blinding?
All outcomes
Unclear risk Participant & clinician: no, outcome assessor: unclear. Trial was
designed to be double-blind, but it ceased when discolouration
due to clofazimine appeared
Incomplete outcome data addressed?
All outcomes
High risk 5 participants lost to follow-up and excluded from analysis
Free of selective reporting? Unclear risk No statistical analysis performed
Free of other bias? Unclear risk No information about baseline characteristics of both groups;
outcome measures not well-described
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Ing 1969
Methods Design: parallel group
Participants Setting: single centre, Singapore
Incl: lepromatous leprosy and ENL (mild, moderate, or severe)
Excl: not stated
M/F: not stated
Age: not stated
Duration: not stated
Severity: 15 mild, 9 moderate, 6 severe
Randomised: 30 participants
Evaluable: 30 participants, though one participants did not complete 4-week treatment
Unit of analysis: individual
Interventions Experimental group (n=16): indomethacin (25 mg 3 times daily) for 1 month
Control group (n=14): prednisolone (5 mg 3 times daily) for 1 month
Other therapy: anti-leprosy drugs were given during 4-week trial period, but no addi-
tional analgesics
Outcomes Improvement after 4 weeks (e.g. mean change in pain relief, subsidence of lesions)
Side-effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Unclear risk No information provided
Incomplete outcome data addressed?
All outcomes
Unclear risk Not clear as to whether participant who did not complete treat-
ment was included in analysis
Free of selective reporting? High risk No statistical evidence, though states “indomethacin is effective
in treating only mild and moderate cases of ENL”
Free of other bias? Unclear risk Not clear as to whether groups were similar at baseline
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Iyer 1971
Methods Design: parallel group
Participants Setting: multicentre, 4 centres, India, Mali, Somalia, Spain
Incl: clearly demonstrable dermatological signs of acute lepra reactions i.e. erythema
nodosum-like lesions or erythema multiforme-like lesions
Excl: severe or life-threatening lepra reactions
M/F: 92 M
Age: 15 to 55+
Duration: not stated
Severity: not stated
Randomised: 214 ENL reactions (of 92 participants)
Evaluable: 214 ENL reactions
Unit of analysis: reaction
Interventions Experimental group (n=116): thalidomide tablets (100 mg 4 times daily if ≥ 50 kg, or
100 mg 1 to 3 times daily if < 50 kg) for 7 days
Control group (n=98): acetylsalicyclic acid tablets (400 mg 4 times daily if ≥ 50 kg, or
400 mg 1 to 3 times daily if < 50 kg) for 7 days
Other therapy: upon admission all drug therapy had to be ceased
Outcomes No further reactions
Changes in temperature, skin lesions, blood pressure, pulse rate, and blood cell count
after 7 days
Side-effects
Notes Each reaction was treated with a 7-day regimen. A new regimen was allocated to a
participant if there was no improvement or if new acute reactions occurred. The statistical
design provided for treatment of 4 reactions in each participant, 2 with acetylsalicyclic
acid, and 2 with thalidomide, the order being random
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Low risk Confidential master sheet of drug allocation kept by WHO,
bottles with tablets labelled by drug manufacturer according to
master sheet
Blinding?
All outcomes
Unclear risk Unclear who were blinded, though states trial was double-blind
Incomplete outcome data addressed?
All outcomes
Unclear risk No mention of attrition in text or tables, suggesting 100%
follow-up
Free of selective reporting? Unclear risk No statistical analysis performed
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Iyer 1971 (Continued)
Free of other bias? Unclear risk No information about baseline characteristics of both groups;
outcome measures not well-described
Iyer 1976
Methods Design: parallel group
Participants Setting: single centre, India
Incl: male, lepromatous leprosy and prone to recurrent reactive episodes
Excl: not stated
M/F: 72 M
Age: 15 to 54
Duration: < 6 months to > 4 years
Severity: moderate, severe
Randomised: unclear, states “72 participants available for analysis”
Evaluable: 72 participants
Unit of analysis: individual
Interventions Experimental group (n=36): clofazimine (100 mg 3 times daily) for 8 weeks, clofazimine
(100 mg once a day) for 52 weeks
Control group (n=36): thalidomide (100 mg 3 times daily) for 8 weeks, thalidomide (25
to 50 mg once a day) for 52 weeks
Other therapy: dapsone (10 mg/kg/week) during 52 weeks maintenance therapy
Outcomes Time-to-control reaction
Maintenance of anti-reaction effect after therapy
Notes First 8 weeks (part A) was acute treatment to control reaction as quickly and effectively
as possible. Part B (52 weeks) was dosage aimed at maintaining effect
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
High risk No, open trial, blinding impossible due to skin discolouration
from clofazimine
Incomplete outcome data addressed?
All outcomes
Unclear risk No mention of attrition in text or tables, suggesting 100%
follow-up
Free of selective reporting? Unclear risk No statistical analysis performed
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Iyer 1976 (Continued)
Free of other bias? Unclear risk Not clear as towhether groupswere similar at baseline; outcome
measures not well-described
Karat 1969
Methods Design: parallel group
Participants Setting: single centre, leprosy centre, India
Incl: lepromatous leprosy with ENL, > 12 years
Excl: history or radiological evidence of peptic ulcer, diabetes, TB, hypertension, severe
intercurrent infection, acute peripheral nerve paralysis, medical conditions requiring use
of other anti-leprosy drugs
M/F: not stated
Age: not stated
Duration: not stated
Severity: 28 mild, 22 severe
Randomised: 50 participants
Evaluable: 50 participants
Unit of analysis: individual
Interventions Group 1 (n=11): indomethacin orally (50 mg 3 times daily) in week 1 to 2, (25 mg 3
times daily) in week 3, (25 mg once a day) maintenance
Group 2 (n=12): chloroquine orally (250 mg 3 times daily) in week 1 to 2, (250 mg 2
times daily) in week 3, (250 mg once a day) maintenance
Group 3 (n=13): prednisolone orally (5 mg 3 times daily) in week 1 to 2, (5 mg 2 times
daily) in week 3, (5 mg once a day) maintenance
Group 4 (n=14): aspirin orally (1 g 3 times daily) in week 1 to 2, (1 g 2 times daily) in
week 3, (500 mg 2 times daily) maintenance
Other therapy: anti-leprosy drugs were stopped on admission; sedation with phenobar-
bitone or chlorpromazine if needed; diuretics only when oedema was progressive and
uncontrolled by one of the given drugs
Outcomes Control of reaction
Recurrence of reaction
Side-effects
Notes Duration of trial period unclear, paper states both trial period of 90 days and 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Unclear, though states “statistically randomised grouping”
Allocation concealment? Unclear risk Unclear, though states was confidential list
Blinding?
All outcomes
Unclear risk Unclear who were blinded, though states trial was double-blind
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Karat 1969 (Continued)
Incomplete outcome data addressed?
All outcomes
Unclear risk No mention of attrition in text or tables, suggesting 100%
follow-up
Free of selective reporting? Low risk
Free of other bias? Unclear risk No information about baseline characteristics of both groups;
outcome measures not well-described
Karat 1970
Methods Design: parallel group
Participants Setting: single centre, leprosy centre, India
Incl: history of ≥ 3 severe reactions and with severe current reaction which could not be
controlled by antimony, aspirin, or chloroquine
Excl: peptic ulcer, intercurrent acute infections, TB, or malignant lesions
M/F: not stated
Age: not stated
Duration: 4 to 150 months
Severity: severe
Randomised: 24 participants
Evaluable: 24 participants
Unit of analysis: individual
Interventions Experimental group (n=12): clofazimine (100 mg 3 times daily) for 12 weeks
Control group (n=12): prednisolone (10 mg 3 times daily) week 1, (10 mg 2 times daily)
week 2, (5 mg 3 times daily) week 3, (10 mg 2 times daily) week 4, (5 mg once daily)
weeks 5 to 12
Other therapy: none
Outcomes Treatment success at end of 12 weeks, defined as body temp < 37.2 ºC, no new ENL
lesions, no pain in peripheral nerve, no progression of neurological deficit, and iritis
quiescent in 2 weeks from starting treatment
Recurrence of reaction during trial
Side-effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Unclear, though states “list of random allocations”
Allocation concealment? Unclear risk Unclear, though states “list was prepared earlier and kept con-
fidential at pharmacy”
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Karat 1970 (Continued)
Blinding?
All outcomes
Unclear risk Unclear who were blinded, though states trial was double-blind
Incomplete outcome data addressed?
All outcomes
Unclear risk No mention of attrition in text or tables, suggesting 100%
follow-up
Free of selective reporting? Low risk
Free of other bias? Low risk
Pearson 1969
Methods Design: cross-over
Participants Setting: single centre, leprosy centre, Malaysia
Incl: moderately severe ENL
Excl: not stated
M/F: 11/1
Age: not stated
Duration: 10 months to 3.5 years
Severity: unclear, though title states was moderately severe ENL
Randomised: 12 participants
Evaluable: 12 participants (1 from group B withdrawn from study after 9 weeks)
Unit of analysis: individual
Interventions Group A (n=not stated): thalidomide tablets (100 mg 3 times daily) for 6 weeks, followed
by placebo (dose and frequency unknown) for 6 weeks
Group B (n=not stated): placebo tablets (dose and frequency not stated) for 6 weeks,
followed by thalidomide tablets (100 mg 3 times daily) for 6 weeks
Other therapy: prednisolone, stibophen, and paracetamol in addition to placebo
Outcomes Change in ENL score
Steroid requirement
Side-effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Unclear risk Participant & clinician: yes, outcome assessor: unclear
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Pearson 1969 (Continued)
Incomplete outcome data addressed?
All outcomes
Low risk Intention-to-treat analysis performed; average scores for first 3
weeks of thalidomide have been inserted for weeks 10 to 12
Free of selective reporting? High risk No statistical evidence, though states “thalidomide was superior
to a placebo”
Free of other bias? Unclear risk No information about baseline characteristics of both groups;
outcome measures not well-described
Sales 2007
Methods Design: parallel group
Participants Setting: single centre, leprosy centre, Brazil
Incl: MB leprosy, males between 18 to 60 years old, females over 49 (postmenopausal),
clinical and histopathological ENL
Excl: Acute neuritis requiring CS, hepatic, renal, mental diseases, diabetes, and/or im-
mune-deficiencies related to HIV
M/F: 38/6
Age: 18 to 69
Duration: not stated
Severity: not stated
Randomised: 44 participants
Evaluable: 44 participants (8 lost to follow-up)
Unit of analysis: individual
Interventions Group A (n=24): pentoxifylline (1.2 g daily) for 30 days
Group B (n=20): thalidomide (300 mg daily) for 30 days
Other therapy: participants with no improvement after 15 days treatment or with severe
adverse effects were removed from study and put on recommended regimen of thalido-
mide or corticosteroids
Outcomes Improvement at end of 30 days treatment, defined as complete elimination of type
2 reactional skin lesion inflammation, normal body temperature, and/or regression of
systemic symptoms
Side-effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Unclear risk No information provided
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Sales 2007 (Continued)
Blinding?
All outcomes
Unclear risk Unclear who were blinded, though states trial was double-
blinded
Incomplete outcome data addressed?
All outcomes
Low risk Intention-to-treat analysis performed; participants removed
from trial were categorised as treatment non-responders
Free of selective reporting? Low risk
Free of other bias? Unclear risk Unclear if all relevant baseline characteristics were similar
Sheskin 1969
Methods Design: parallel group
Participants Setting: single centre, hospital/ambulatory, Venezuela
Incl: lepromatous leprosy with clearly demonstrable dermatologic, neurologic, or other
manifestations of ENL reaction
Excl: not stated
M/F: 37/15
Age: 17 to 58
Duration: 3 months to 9 years
Severity: not stated
Randomised: 173 ENL reactions (of 52 participants)
Evaluable: 173 ENL reactions
Unit of analysis: reaction
Interventions Experimental group (n=85): thalidomide tablets (100 mg 4 times daily if > 50 kg, or 6
mg/kg/day if ≤ 50 kg) for 7 days
Control group (n=88): placebo tablets (100 mg 4 times daily if > 50 kg, or 6 mg/kg/day
if ≤ 50 kg) for 7 days
Other therapy: if on sulfone therapy at admission, sulfone therapy was continued; if
receiving steroids or adrenocorticotropic hormone (ACTH) for prolonged periods at
admission, same dosage was continued
Outcomes Total improvement, defined as all dermatologic manifestations in advanced state of
remission, no new elements, disappearance of characteristic lepra reaction symptoms
after 7 days
Side-effects
Notes Each reaction was treated with a 7-day regimen. A new regimen was allocated to a
participant if there was no improvement. Up to 4 consecutive treatment regimens were
given to each participants
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
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Sheskin 1969 (Continued)
Allocation concealment? Unclear risk Unclear, though states “code unknown to investigators and kept
elsewhere”
Blinding?
All outcomes
Unclear risk Unclear who were blinded, though states trial was double-blind
Incomplete outcome data addressed?
All outcomes
Unclear risk No mention of attrition in text or tables, suggesting 100%
follow-up
Free of selective reporting? Low risk
Free of other bias? Unclear risk Not clear as to whether groups were similar at baseline
Villahermosa 2005
Methods Design: parallel group
Participants Setting: single centre, leprosy centre, Philippines
Incl: lepromatous leprosy, ≥ 18 years, acute histologically confirmed episode of ENL
consisting of ≥ 10 skin nodules, with or without systemic symptoms; women only
included if evidence of non-childbearing potential
Excl: incapacitating ENL (bed ridden), severe neuritis, thalidomide ingestion within 30
days or corticosteroid ingestion within 2 weeks of enrollment
M/F: 22 M
Age: 18 to 46
Duration: 0 to 3 years
Severity: not stated
Randomised: 22 participants
Evaluable: 19 (3 lost to follow-up)
Unit of analysis: individual
Interventions Group A (n=12): thalidomide capsules, 100 mg daily (2x 50 mg, 4x dummy capsules) in
week 1, 50 mg daily (1x 50 mg, 3x dummy capsules) in week 2 to 3, 4x dummy capsules
daily in weeks 4 to 7
Group B (n=10): thalidomide capsules, 300 mg daily (6x 50 mg, 0x dummy capsules)
in week 1, 200 mg daily (4x 50 mg, 0x dummy capsules) in week 2 to 3, 100 mg daily
(2x 50 mg, 2x dummy capsules) in week 4 to 5, 50 mg daily (1x 50 mg, 3x dummy
capsules) in week 6 to 7
Other therapy: acetaminophen for participants with fever during first 72 hours of study
Outcomes Resolution of inflamed ENL nodules during initial 7-day treatment
Global assessment
Re-emergence of skin lesions during taper
Week 7 lesion counts
Recurrence of lesions after taper
Safety and adverse events
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Villahermosa 2005 (Continued)
Notes Week 1 treatment was acute treatment. Participants with complete or partial responses
at week 1 were tapered from thalidomide during weeks 2 to 7
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Low risk Adequate, coded blister packs by pharmaceutical company
Blinding?
All outcomes
Unclear risk Participant: yes, clinician & outcome assessor: unclear; though
states was double-blind
Incomplete outcome data addressed?
All outcomes
High risk Three participants withdrawn from trial and excluded from
analysis
Free of selective reporting? Low risk
Free of other bias? Unclear risk Unclear if all relevant baseline characteristics were similar
Waters 1971
Methods Design: cross-over
Participants Setting: single centre, leprosy centre, Malaysia
Incl: not stated, but included were participants with lepromatous leprosy and histologi-
cally confirmed moderately severe or severe chronic ENL
Excl: not stated
M/F: 10 M
Age: 19 to 56
Duration: 9 months to 3.5 years
Severity: moderately severe or severe chronic ENL
Randomised: 9 participants for first 16-week trial, 8 participants for second 24-week
trial
Evaluable: 9 participants for first 16-week trial, 8 participants for second 24-week trial
Unit of analysis: individual
Interventions 16-week trial (n=9) and 24-week trial (n=8):
Group A (n=5 or n=3): thalidomide tablets (100 mg 3 times daily) for 4 or 6 weeks,
followed by placebo tablets (dose unknown, 3 times daily) for 4 or 6 weeks
Group B (n=4 or n=5): placebo tablets (dose unknown, 3 times daily) for 4 or 6 weeks,
followed by thalidomide tablets (100 mg 3 times daily) for 4 or 6 weeks
Other therapy: 100 mg dapsone twice weekly, prednisolone or corticotrophin daily, mild
analgesics if needed
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Waters 1971 (Continued)
Outcomes Steroid requirement during trial period
ENL score (temperature, severity)
Notes First trial lasted 16 weeks (4 weeks control, 4 weeks A, 4 weeks B, 4 weeks control). The
second trial started 11 weeks after completion of first trial. The trial lasted 24 weeks (6
weeks control, 6 weeks A, 6 weeks B, 6 weeks control) and included 8 participants of
which 7 participated in the first trial
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk No information provided
Allocation concealment? Unclear risk Unclear, though states “the code of drug allocation was not re-
vealed to anyone until after the trial was completed”
Blinding?
All outcomes
Unclear risk Participant & clinician: yes, outcome assessor: unclear
Incomplete outcome data addressed?
All outcomes
Unclear risk No mention of attrition in text or tables, suggesting 100% fol-
low-up
Free of selective reporting? High risk No statistical evidence, though states “nine of the ten partic-
ipants showed a very significant reduction in steroid require-
ment”
Free of other bias? Unclear risk Not clear as to whether groups were similar at baseline
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anonymous 1976 Treatment of lepromatous leprosy, not of ENL
Arruda 1986 Treatment of lepromatous leprosy, not of ENL
Browne 1981 No RCT
Dawlah 2002 No RCT
de Almeida Neto 1981 No separate results for ENL
de Carsalade 2003 No RCT
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(Continued)
Garbino 2006 No specific treatment of ENL, but treatment of ulnar neuropathy in participants with type 1 and type 2
reactions
Hastings 1970 No RCT
Huang 1987 No RCT
Imkamp 1968 No RCT
Imkamp 1973 No RCT
Jamet 1992 Treatment of lepromatous leprosy, not of ENL
Kar 1988 Randomisation by alternation
Karat 1971a Treatment of lepromatous leprosy, not of ENL
Karat 1971b Propylaxis treatment, not treatment of ENL
Levy 1973 No RCT
Manungo 1982a Treatment of lepromatous leprosy, not of ENL
Manungo 1982b No RCT
Moreira 1998 No RCT
Partida-Sanchez 1998 No RCT
Penna 2005 Only methodology and intake results were described, trial not completed
Pettit 1967 No RCT
Plock 1976 No RCT
Ramu 1979 Randomisation by alternation
Rodriguez 1974 Treatment of lepromatous and borderline leprosy, not of ENL
Sharma 1982 No RCT
Sharma 1986 No RCT
Sheskin 1969a No RCT
Sheskin 1971 No RCT
Sheskin 1983 No RCT
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(Continued)
Sunderkotter 2005 No RCT
Vides 1999 No RCT
Zaheer 1993 Treatment of multibacillary (MB) leprosy, not of ENL
Zhang 2008 No RCT
Characteristics of ongoing studies [ordered by study ID]
Salim 2009
Trial name or title Montelukast in ENL Reaction
Methods design: parallel groups
randomised controlled trial
single blind
Participants • MB leprosy
• ENL reaction
• age 15 to 65
• weight > 35kg
• patient willing to participate, including agreeing to investigations and admission
• adequate past records
• no steroid received in past 4 weeks
Interventions 1) prednisolone alone
2) prednisolone plus montelukast
3) montelukast alone
Prednisolone starting at 40 mg daily tapered over 12 weeks. Montelukast 10 mg for 16 weeks
Outcomes • absence of new nerve function impairment
• decrease in ENL score
• incidence of adverse effects
Timing of outcome assessment at 24 weeks
Starting date December 2006
Contact information Abdul H Salim, MBBS: dfsalim@citechco.net
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Thalidomide versus aspirin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Remission of skin lesions 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 2. 100 mg thalidomide versus 300 mg thalidomide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Remission of skin lesions 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Change in ENL severity
(proportion improved)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Time to next clinical ENL
episode
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Adverse effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 3. Pentoxifylline versus thalidomide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Remission of skin lesions 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 4. Clofazimine versus prednisolone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Remission of skin lesions 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Time to next clinical ENL
episode
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Adverse effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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Comparison 5. Clofazimine versus thalidomide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to next clinical ENL
episode
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 6. Indomethacin versus prednisolone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Remission of skin lesions 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Change in ENL severity
(proportion improved)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Time to next clinical ENL
episode
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Adverse effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 7. Indomethacin versus chloroquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in ENL severity
(proportion improved)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Time to next clinical ENL
episode
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Adverse effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 8. Indomethacin versus aspirin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in ENL severity
(proportion improved)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Time to next clinical ENL
episode
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Adverse effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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Comparison 9. Levamisole versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in ENL severity
(proportion improved)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Thalidomide versus aspirin, Outcome 1 Remission of skin lesions.
Review: Interventions for erythema nodosum leprosum
Comparison: 1 Thalidomide versus aspirin
Outcome: 1 Remission of skin lesions
Study or subgroup thalidomide aspirin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Iyer 1971 26/50 9/42 2.43 [ 1.28, 4.59 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 26 (thalidomide), 9 (aspirin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours aspirin Favours thalidomide
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Analysis 2.1. Comparison 2 100 mg thalidomide versus 300 mg thalidomide, Outcome 1 Remission of skin
lesions.
Review: Interventions for erythema nodosum leprosum
Comparison: 2 100 mg thalidomide versus 300 mg thalidomide
Outcome: 1 Remission of skin lesions
Study or subgroup 100 mg thalidomide 300 mg thalidomide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Villahermosa 2005 8/12 5/10 1.33 [ 0.64, 2.79 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (100 mg thalidomide), 5 (300 mg thalidomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours 300mg thalidomide Favours 100mg thalidomide
Analysis 2.2. Comparison 2 100 mg thalidomide versus 300 mg thalidomide, Outcome 2 Change in ENL
severity (proportion improved).
Review: Interventions for erythema nodosum leprosum
Comparison: 2 100 mg thalidomide versus 300 mg thalidomide
Outcome: 2 Change in ENL severity (proportion improved)
Study or subgroup 100 mg thalidomide 300 mg thalidomide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Villahermosa 2005 10/12 5/10 1.67 [ 0.85, 3.26 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 10 (100 mg thalidomide), 5 (300 mg thalidomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours 300mg thalidomide Favours 100mg thalidomide
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Analysis 2.3. Comparison 2 100 mg thalidomide versus 300 mg thalidomide, Outcome 3 Time to next
clinical ENL episode.
Review: Interventions for erythema nodosum leprosum
Comparison: 2 100 mg thalidomide versus 300 mg thalidomide
Outcome: 3 Time to next clinical ENL episode
Study or subgroup 100 mg thalidomide 300 mg thalidomide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Villahermosa 2005 6/8 1/5 3.75 [ 0.62, 22.64 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 6 (100 mg thalidomide), 1 (300 mg thalidomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours 100mg thalidomide Favours 300mg thalidomide
Analysis 2.4. Comparison 2 100 mg thalidomide versus 300 mg thalidomide, Outcome 4 Adverse effects.
Review: Interventions for erythema nodosum leprosum
Comparison: 2 100 mg thalidomide versus 300 mg thalidomide
Outcome: 4 Adverse effects
Study or subgroup 100 mg thalidomide 300 mg thalidomide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Villahermosa 2005 5/12 9/10 0.46 [ 0.23, 0.93 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (100 mg thalidomide), 9 (300 mg thalidomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours 100mg thalidomide Favours 300mg thalidomide
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Analysis 3.1. Comparison 3 Pentoxifylline versus thalidomide, Outcome 1 Remission of skin lesions.
Review: Interventions for erythema nodosum leprosum
Comparison: 3 Pentoxifylline versus thalidomide
Outcome: 1 Remission of skin lesions
Study or subgroup pentoxifylline thalidomide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sales 2007 12/14 9/11 1.05 [ 0.74, 1.49 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (pentoxifylline), 9 (thalidomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours thalidomide Favours pentoxifylline
Analysis 4.1. Comparison 4 Clofazimine versus prednisolone, Outcome 1 Remission of skin lesions.
Review: Interventions for erythema nodosum leprosum
Comparison: 4 Clofazimine versus prednisolone
Outcome: 1 Remission of skin lesions
Study or subgroup clofazimine prednisolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1970 11/12 3/12 3.67 [ 1.36, 9.91 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 11 (clofazimine), 3 (prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours prednisolone Favours clofazimine
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Analysis 4.2. Comparison 4 Clofazimine versus prednisolone, Outcome 2 Time to next clinical ENL episode.
Review: Interventions for erythema nodosum leprosum
Comparison: 4 Clofazimine versus prednisolone
Outcome: 2 Time to next clinical ENL episode
Study or subgroup clofazimine prednisolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1970 1/11 2/3 0.14 [ 0.02, 1.04 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (clofazimine), 2 (prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours clofazimine Favours prednisolone
Analysis 4.3. Comparison 4 Clofazimine versus prednisolone, Outcome 3 Adverse effects.
Review: Interventions for erythema nodosum leprosum
Comparison: 4 Clofazimine versus prednisolone
Outcome: 3 Adverse effects
Study or subgroup clofazimine prednisolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1970 12/12 6/12 1.92 [ 1.10, 3.35 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (clofazimine), 6 (prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours clofazimine Favours prednisolone
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Analysis 5.1. Comparison 5 Clofazimine versus thalidomide, Outcome 1 Time to next clinical ENL episode.
Review: Interventions for erythema nodosum leprosum
Comparison: 5 Clofazimine versus thalidomide
Outcome: 1 Time to next clinical ENL episode
Study or subgroup clofazimine thalidomide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Iyer 1976 1/36 13/36 0.08 [ 0.01, 0.56 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (clofazimine), 13 (thalidomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours clofazimine Favours thalidomide
Analysis 6.1. Comparison 6 Indomethacin versus prednisolone, Outcome 1 Remission of skin lesions.
Review: Interventions for erythema nodosum leprosum
Comparison: 6 Indomethacin versus prednisolone
Outcome: 1 Remission of skin lesions
Study or subgroup indomethacin prednisolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ing 1969 8/16 3/14 2.33 [ 0.76, 7.13 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (indomethacin), 3 (prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours prednisolone Favours indomethacin
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Analysis 6.2. Comparison 6 Indomethacin versus prednisolone, Outcome 2 Change in ENL severity
(proportion improved).
Review: Interventions for erythema nodosum leprosum
Comparison: 6 Indomethacin versus prednisolone
Outcome: 2 Change in ENL severity (proportion improved)
Study or subgroup indomethacin prednisolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 7/11 13/13 0.65 [ 0.41, 1.02 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (indomethacin), 13 (prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours prednisolone Favours indomethacin
Analysis 6.3. Comparison 6 Indomethacin versus prednisolone, Outcome 3 Time to next clinical ENL
episode.
Review: Interventions for erythema nodosum leprosum
Comparison: 6 Indomethacin versus prednisolone
Outcome: 3 Time to next clinical ENL episode
Study or subgroup indomethacin prednisolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 4/7 9/13 0.83 [ 0.40, 1.72 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (indomethacin), 9 (prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours indomethacin Favours prednisolone
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Analysis 6.4. Comparison 6 Indomethacin versus prednisolone, Outcome 4 Adverse effects.
Review: Interventions for erythema nodosum leprosum
Comparison: 6 Indomethacin versus prednisolone
Outcome: 4 Adverse effects
Study or subgroup indomethacin prednisolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 7/11 9/13 0.92 [ 0.52, 1.63 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (indomethacin), 9 (prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours indomethacin Favours prednisolone
Analysis 7.1. Comparison 7 Indomethacin versus chloroquine, Outcome 1 Change in ENL severity
(proportion improved).
Review: Interventions for erythema nodosum leprosum
Comparison: 7 Indomethacin versus chloroquine
Outcome: 1 Change in ENL severity (proportion improved)
Study or subgroup indomethacin chloroquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 7/11 8/12 0.95 [ 0.52, 1.74 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (indomethacin), 8 (chloroquine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours chloroquine Favours indomethacin
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Analysis 7.2. Comparison 7 Indomethacin versus chloroquine, Outcome 2 Time to next clinical ENL
episode.
Review: Interventions for erythema nodosum leprosum
Comparison: 7 Indomethacin versus chloroquine
Outcome: 2 Time to next clinical ENL episode
Study or subgroup indomethacin chloroquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 4/7 4/8 1.14 [ 0.44, 2.94 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (indomethacin), 4 (chloroquine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours indomethacin Favours chloroquine
Analysis 7.3. Comparison 7 Indomethacin versus chloroquine, Outcome 3 Adverse effects.
Review: Interventions for erythema nodosum leprosum
Comparison: 7 Indomethacin versus chloroquine
Outcome: 3 Adverse effects
Study or subgroup indomethacin chloroquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 7/11 7/12 1.09 [ 0.57, 2.10 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (indomethacin), 7 (chloroquine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours indomethacin Favours chloroquine
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Analysis 8.1. Comparison 8 Indomethacin versus aspirin, Outcome 1 Change in ENL severity (proportion
improved).
Review: Interventions for erythema nodosum leprosum
Comparison: 8 Indomethacin versus aspirin
Outcome: 1 Change in ENL severity (proportion improved)
Study or subgroup indomethacin aspirin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 7/11 10/14 0.89 [ 0.51, 1.55 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (indomethacin), 10 (aspirin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours aspirin Favours indomethacin
Analysis 8.2. Comparison 8 Indomethacin versus aspirin, Outcome 2 Time to next clinical ENL episode.
Review: Interventions for erythema nodosum leprosum
Comparison: 8 Indomethacin versus aspirin
Outcome: 2 Time to next clinical ENL episode
Study or subgroup indomethacin aspirin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 4/7 7/10 0.82 [ 0.38, 1.74 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (indomethacin), 7 (aspirin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours indomethacin Favours aspirin
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Analysis 8.3. Comparison 8 Indomethacin versus aspirin, Outcome 3 Adverse effects.
Review: Interventions for erythema nodosum leprosum
Comparison: 8 Indomethacin versus aspirin
Outcome: 3 Adverse effects
Study or subgroup indomethacin aspirin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karat 1969 7/11 4/14 2.23 [ 0.87, 5.71 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (indomethacin), 4 (aspirin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours indomethacin Favours aspirin
Analysis 9.1. Comparison 9 Levamisole versus placebo, Outcome 1 Change in ENL severity (proportion
improved).
Review: Interventions for erythema nodosum leprosum
Comparison: 9 Levamisole versus placebo
Outcome: 1 Change in ENL severity (proportion improved)
Study or subgroup levamisole placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Arora 1985 4/7 3/5 0.95 [ 0.36, 2.49 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (levamisole), 3 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours placebo Favours levamisole
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A P P E N D I C E S
Appendix 1. Cochrane Library search strategy
#1(type 2 leprosy):ti,ab,kw or (lepr* reaction):ti,ab,kw or (erythema nodosum) or (erythema nodosum leprosum) or ’ENL’:ti,ab,kw or
(borderline leprosy):ti,ab,kw or (lepromatous leprosy):ti,ab,kw
#2MeSH descriptor Leprosy, Borderline, this term only
#3MeSH descriptor Leprosy, Lepromatous, this term only
#4(SR-SKIN)
#5(#1 OR #2 OR #3)
#6(#5 AND NOT #4)
Appendix 2. MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. humans.sh.
10. 8 and 9
11. leprosy.mp. or exp LEPROSY/
12. type 2 reaction.mp.
13. lepra reaction.mp.
14. ENL.mp.
15. *Erythema Nodosum/
16. LEPROSY, BORDERLINE/
17. LEPROSY, LEPROMATOUS/
18. 11 and 12
19. 11 and 14
20. 15 or 16 or 17 or 18 or 19
21. 10 and 20
Appendix 3. EMBASE search strategy
1. random$.mp.
2. factorial$.mp.
3. crossover$.mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
7. assign$.mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
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13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. leprosy.mp. or exp LEPROSY/
15. type 2 reaction.mp.
16. 14 and 15
17. lepra reaction.mp.
18. erythema nodosum leprosum.mp. or exp Erythema Nodosum Leprosum/
19. ENL.mp.
20. borderline leprosy.mp. or exp Borderline Leprosy/
21. lepromatous leprosy.mp. or exp Lepromatous Leprosy/
22. 16 or 17 or 18 or 19 or 20 or 21
23. 13 and 22
Appendix 4. AMED search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. humans.sh.
10. 8 and 9
11. leprosy.mp. or exp LEPROSY/
12. type 2 reaction.mp.
13. 11 or 12
14. 10 and 13
Appendix 5. LILACS search strategy
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or
tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw
clinic$)) ANDNOT ((CT ANIMALS ORMH ANIMALS OR CT RABBITS OR CTMICE ORMH RATS ORMH PRIMATES
OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Palavras] and ((eritema
nudoso leprso) or lepra or (leprorreacion) [Palavras] or lepra lepromatosa) or (lepra bipolar) or (lepra dimorfa intermedia) [Palavras]
Appendix 6. CINAHL search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. humans.sh.
10. 8 and 9
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11. leprosy.tx.
12. type 2 reaction.tx.
13. erythema nodosum leprosum.tx.
14. 11 and 12
15. 11 and 13
16. 14 or 15
9. 10 and 16.
WH A T ’ S N E W
Last assessed as up-to-date: 11 March 2009.
Date Event Description
12 September 2012 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 3, 2009
Date Event Description
6 June 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Link with editorial base and co-ordinate contributions from co-authors (NvV)
Draft protocol (NvV, DL, WvB, JRJ, JHR)
Run search (NvV, FD)
Identify relevant titles and abstracts from searches (NvV, JHR)
Obtain copies of trials (NvV)
Selection of trials (NvV, JHR)
Extract data from trials (NvV)
Enter data into RevMan (NvV) Check data (JHR)
Carry out analysis (NvV, JHR)
Interpret data (NvV, DL, WvB, JHR)
Draft final review (NvV, DL, WvB, JRJ, JHR)
Update review (NvV)
Guarantor review (NvV)
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D E C L A R A T I O N S O F I N T E R E S T
DNL has been a paid advisor to the drug company Pharmion (who makes thalidomide) advising them on their application to have
thalidomide registered within the EU.
S O U R C E S O F S U P P O R T
Internal sources
• The Netherlands Leprosy Relief, Netherlands.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the original published protocol outcomes recorded for four weeks or less from the start of treatment were considered to reflect short-
term benefit, and data that were recorded for three months or longer from the start of treatment were considered long-term outcomes.
After extracting data, we found that timing of outcome assessment varied between four days and one year from the start of treatment.
We decided that studies with outcomes of four weeks or less from the start of treatment were considered as short-term outcomes. We
added medium-term outcomes defined as outcomes between four weeks and six months from the start of treatment and changed long-
term outcome assessment to more than six months from the start of treatment.
In the original published protocol we planned for two authors to independently extract the data, but it was more efficient to have one
author extract the data and enter it into Review Manager, and a second author to check the data.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Aspirin [therapeutic use]; Clofazimine [therapeutic use]; Erythema Nodosum [∗drug therapy]; Leprostatic Agents [∗therapeutic use];
Leprosy, Lepromatous [∗drug therapy]; Prednisolone [therapeutic use]; Randomized Controlled Trials as Topic; Remission Induction;
Thalidomide [therapeutic use]
MeSH check words
Humans
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